New drug combo shows promise against hodgkin lymphoma
NCT ID NCT07171827
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study compared two chemotherapy regimens for people with advanced classical Hodgkin lymphoma. One group received the standard ABVD regimen, while the other received a newer combination called BV+AVD, which includes the targeted drug brentuximab vedotin. The trial enrolled 60 patients and measured how long they lived without the cancer getting worse, overall response, and side effects. Results may help determine if the newer combination is a better first treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
- What this could lead to
- If BV+AVD proves better, it could become a new standard first treatment for advanced Hodgkin lymphoma, potentially improving survival and reducing side effects.
- What could go wrong
- This is a small, single-center study with only 60 participants, so results may not apply broadly. The comparison is against an established regimen, and any benefit may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Helwan University
Helwan, 11795, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.